F. , C. Dw, J. Tp, M. , P. W. Fkl et al., or revising it critically for important intellectual content, and all authors approved the final version to be published. PC had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis PC were involved in the acquisition of data. FKL, CP, and PC were involved in the analysis and interpretation of data Competing interests DW has received consulting fees, speaking fees and/or honoraria from Abbott, Amgen, Wyeth-Pfizer, Roche, Chugai, Bristol-Myers Squibb, and Schering-Plough (< $10,000 each), and was investigator for Roche Chugai, Sanofi Aventis, and Novartis. MS has received consulting fees, speaking fees, and/or honoraria from Roche JMB has received consulting fees, speaking fees, and/or honoraria from Roche (< $10,000 each) PGa has received consulting fees, speaking fees and/or honoraria from Abbott, Wyeth-Pfizer, and Roche Chugai (< $10,000 each) PGo has received consulting fees, speaking fees and/or honoraria from Abbott, Wyeth-Pfizer, Roche, Chugai, Bristol-Myers Squibb, Schering-Plough, and MSD (< $10,000 each), and was investigator for Abbott, Wyeth-Pfizer, Roche Chugai, and Bristol-Myers Squibb. TP has received consulting fees, speaking fees and/or honoraria from Abbott, avenue du Général Sarrail, 94000 Créteil, France. Authors' contributions All authors were involved in drafting the article the study conception and design-Myers Squibb, and Schering- Plough (< $10,000 each), and was investigator for Roche Chugai, Sanofi Aventis, and Novartis. JS has received consulting fees, speaking fees, and/or honoraria from Pfizer (Wyeth), MSD (Schering Plough), and Roche France (< $10,000 each). PC has received consulting fees, speaking fees and/or honoraria from Abbott-Plough, and UCB (< $10,000 each), and was investigator for Roche Chugai Wyeth-Pfizer, and BMS (< $10,000 each). FKL, CP, MDB, ET, RB, MP, and VF declare that they have no competing interests, p.27, 2011.

J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten et al., Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial, The Lancet, vol.359, issue.9313, pp.1187-1193, 2002.
DOI : 10.1016/S0140-6736(02)08215-6

A. Calin, B. Dijkmans, P. Emery, M. Hakala, J. Kalden et al., Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis, Annals of the Rheumatic Diseases, vol.63, issue.12, pp.1594-1600, 2004.
DOI : 10.1136/ard.2004.020875

D. Van-der-heijde, A. Kivitz, M. Schiff, J. Sieper, B. Dijkmans et al., Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, vol.62, issue.7, pp.2136-2146, 2006.
DOI : 10.1002/art.21913

P. Mease, D. Gladman, C. Ritchlin, E. Ruderman, S. Steinfeld et al., Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial, Arthritis & Rheumatism, vol.52, issue.10, pp.3279-3289, 2005.
DOI : 10.1002/art.21306

C. Antoni, G. Krueger, K. De-vlam, C. Birbara, A. Beutler et al., Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial, Annals of the Rheumatic Diseases, vol.64, issue.8, pp.1150-1157, 2005.
DOI : 10.1136/ard.2004.032268

P. Mease, B. Goffe, J. Metz, A. Vanderstoep, B. Finck et al., Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial, The Lancet, vol.356, issue.9227, pp.385-390, 2000.
DOI : 10.1016/S0140-6736(00)02530-7

B. Glintborg, M. Østergaard, L. Dreyer, N. Krogh, U. Tarp et al., Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated Lekpa et al. Arthritis Research & TherapyR53 with anti-tumor necrosis factor ? therapy: results from the nationwide Danish DANBIO registry, Arthritis Rheum, vol.1414, issue.63, pp.53-382, 2011.

B. Glintborg, M. Ostergaard, N. Krogh, L. Dreyer, H. Kristensen et al., Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry, Annals of the Rheumatic Diseases, vol.69, issue.11, pp.2002-2008, 2010.
DOI : 10.1136/ard.2009.124446

J. Cohen, Successful treatment of psoriatic arthritis with rituximab, Annals of the Rheumatic Diseases, vol.67, issue.11, pp.1647-1348, 2008.
DOI : 10.1136/ard.2007.085290

C. Rodríguez-escalera and A. Fernández-nebro, The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B, Rheumatology, vol.47, issue.11, pp.1732-1733, 2008.
DOI : 10.1093/rheumatology/ken362

J. Cañete, R. Celis, V. Hernández, J. Pablos, and R. Sanmartí, Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis, Annals of the Rheumatic Diseases, vol.69, issue.5, pp.935-936, 2010.
DOI : 10.1136/ard.2009.113233

F. Vieira, M. Callado, and W. Vieira, Abatacept as an option therapy in difficult to treat psoriatic arthritis, Rheumatology International, vol.10, issue.Suppl 1, pp.849-850, 2010.
DOI : 10.1007/s00296-009-1041-1

P. Mease, M. Genovese, M. Genovese, G. Gladstein, A. Kivitz et al., Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial, Arthritis & Rheumatism, vol.48, issue.Suppl 1, pp.939-948, 2011.
DOI : 10.1002/art.30176

D. Wendling, B. Augé, G. Streit, E. Toussirot, and S. Mathieu, Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis, Joint Bone Spine, vol.75, issue.4, pp.510-511, 2008.
DOI : 10.1016/j.jbspin.2008.01.023
URL : https://hal.archives-ouvertes.fr/hal-00465187

I. Song, F. Heldmann, M. Rudwaleit, J. Listing, H. Appel et al., Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial, Arthritis & Rheumatism, vol.6, issue.Suppl II, pp.1290-1297, 2010.
DOI : 10.1002/art.27383

G. Nocturne, M. Dougados, A. Constantin, C. Richez, J. Sellam et al., Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry, Annals of the Rheumatic Diseases, vol.69, issue.2, pp.471-472, 2010.
DOI : 10.1136/ard.2008.107102
URL : https://hal.archives-ouvertes.fr/hal-00503880

I. Song, F. Heldmann, M. Rudwaleit, H. Haibel, A. Weiß et al., Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study, Annals of the Rheumatic Diseases, vol.70, issue.6, pp.1108-1110, 2011.
DOI : 10.1136/ard.2010.145946

F. Lekpa, V. Farrenq, F. Canouï-poitrine, M. Paul, C. X. Bruckert et al., Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition, Joint Bone Spine, vol.79, issue.1, pp.47-50, 2012.
DOI : 10.1016/j.jbspin.2011.02.018

J. Gratacós, A. Collado, X. Filella, R. Sanmartí, J. Cañete et al., SERUM CYTOKINES (IL-6, TNF-??, IL-1?? AND IFN-??) IN ANKYLOSING SPONDYLITIS: A CLOSE CORRELATION BETWEEN SERUM IL-6 AND DISEASE ACTIVITY AND SEVERITY, Rheumatology, vol.33, issue.10, pp.927-931, 1994.
DOI : 10.1093/rheumatology/33.10.927

Z. Tutuncu, A. Bilgie, L. Kennedy, and A. Calin, Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis., Annals of the Rheumatic Diseases, vol.53, issue.6, pp.425-426, 1994.
DOI : 10.1136/ard.53.6.425-b

P. Claudepierre, J. Rymer, F. Authier, Y. Allanore, B. Larget-piet et al., A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies, Rheumatology, vol.36, issue.3, pp.400-401, 1997.
DOI : 10.1093/rheumatology/36.3.400

G. Alenius and C. Eriksson, Rantapää Dahlqvist S: Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?, Clin Exp Rheumatol, vol.27, pp.120-123, 2009.

R. François, L. Neure, J. Sieper, and J. Braun, Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor ?? in two patients with early disease and transforming growth factor ?? in three more advanced cases, Annals of the Rheumatic Diseases, vol.65, issue.6, pp.713-720, 2006.
DOI : 10.1136/ard.2005.037465

N. Nishimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi et al., Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study, Annals of the Rheumatic Diseases, vol.68, issue.10, pp.1580-1584, 2009.
DOI : 10.1136/ard.2008.092866

D. Wendling, E. Racadot, E. Toussirot, and J. Wijdenes, Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy, Rheumatology, vol.35, issue.12, p.1330, 1996.
DOI : 10.1093/rheumatology/35.12.1330

L. Brulhart, M. Nissen, P. Chevallier, and C. Gabay, Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists, Joint Bone Spine, vol.77, issue.6, pp.625-626, 2010.
DOI : 10.1016/j.jbspin.2010.08.004

T. Tanaka, Y. Kuwahara, Y. Shima, T. Hirano, M. Kawai et al., Successful treatment of reactive arthritis with a humanized anti??????interleukin-6 receptor antibody, tocilizumab, Arthritis & Rheumatism, vol.35, issue.12, pp.1762-1764, 2009.
DOI : 10.1002/art.24899

J. Henes, M. Horger, I. Guenaydin, L. Kanz, and I. Koetter, Mixed response to tocilizumab for ankylosing spondylitis, Annals of the Rheumatic Diseases, vol.69, issue.12, pp.2217-2218, 2010.
DOI : 10.1136/ard.2009.126706

D. Wendling, M. Bossert, and C. Prati, Short-term effect of IL-6 inhibition in spondylarthritis, Joint Bone Spine, vol.77, issue.6, pp.624-625, 2010.
DOI : 10.1016/j.jbspin.2010.09.011

M. Mihara, N. Nishimoto, and Y. Ohsugi, The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody, Expert Opinion on Biological Therapy, vol.10, issue.5, pp.683-690, 2005.
DOI : 10.1016/0165-5728(91)90020-8

M. Rudwaleit, D. Van-der-heijde, R. Landewé, J. Listing, N. Akkoc et al., The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection, Annals of the Rheumatic Diseases, vol.68, issue.6, pp.777-783, 2009.
DOI : 10.1136/ard.2009.108233

M. Rudwaleit, D. Van-der-heijde, R. Landewé, N. Akkoc, J. Brandt et al., The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general, Annals of the Rheumatic Diseases, vol.70, issue.1, pp.25-31, 2011.
DOI : 10.1136/ard.2010.133645

S. Van-der-linden and H. Valkenburg, Evaluation of Diagnostic Criteria for Ankylosing Spondylitis, Arthritis & Rheumatism, vol.2, issue.4, pp.361-368, 1984.
DOI : 10.1002/art.1780270401

B. Amor, M. Dougados, and M. Mijiyawa, Criteria of the classification of spondylarthropathies, Rev Rhum Mal Osteoartic, vol.57, pp.85-89, 1990.

M. Dougados, S. Van-der-linden, R. Juhlin, B. Huitfeldt, B. Amor et al., The European Spondylarthropathy Study Group Preliminary Criteria for the Classification of Spondylarthropathy, Arthritis & Rheumatism, vol.57, issue.10, pp.1218-1227, 1991.
DOI : 10.1002/art.1780341003

W. Taylor, D. Gladman, P. Helliwell, A. Marchesoni, P. Mease et al., Classification criteria for psoriatic arthritis: Development of new criteria from a large international study, Arthritis & Rheumatism, vol.59, issue.8, pp.2665-2673, 2006.
DOI : 10.1002/art.21972

J. Braun, J. Davis, M. Dougados, J. Sieper, S. Van-der-linden et al., First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis, Annals of the Rheumatic Diseases, vol.65, issue.3, pp.316-320, 2006.
DOI : 10.1136/ard.2005.040758

J. Dudler and B. Aubry-rozier, Tocilizumab in axial spondylarthritis: about 18 cases, Ann Rheum Dis, vol.70, p.128, 2011.

D. Castillo-piñol, N. Gossec, L. Sparsa, L. Roux, C. Dougados et al., Tocilizumab for treatment of refractory spondylarthritis: report of 5 patients, Ann Rheum Dis, vol.70, p.343, 2011.

S. Hayer, B. Niederreiter, I. Nagelreiter, J. Smolen, and K. Redlich, Interleukin 6 is not a crucial regulator in an animal model of tumour necrosis factor-mediated bilateral sacroiliitis, Annals of the Rheumatic Diseases, vol.69, issue.7, pp.1403-1406, 2010.
DOI : 10.1136/ard.2010.129148

A. Bennett, A. Tan, L. Coates, P. Emery, H. Marzo-ortega et al., Sustained response to anakinra in ankylosing spondylitis, Rheumatology, vol.47, issue.2, pp.223-224, 2008.
DOI : 10.1093/rheumatology/kem302

H. Haibel, M. Rudwaleit, J. Listing, and J. Sieper, Open label trial of anakinra in active ankylosing spondylitis over 24 weeks, Annals of the Rheumatic Diseases, vol.64, issue.2, pp.296-298, 2005.
DOI : 10.1136/ard.2004.023176

N. Jung, M. Hellmann, R. Hoheisel, C. Lehmann, I. Haase et al., An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX), Clinical Rheumatology, vol.42, issue.Suppl 2, pp.1169-1173, 2010.
DOI : 10.1007/s10067-010-1504-5

D. Wendling and C. Prati, Biologic agents for treating ankylosing spondylitis: Beyond TNF?? antagonists, Joint Bone Spine, vol.78, issue.6, pp.542-544, 2011.
DOI : 10.1016/j.jbspin.2011.05.023